Results 141 to 150 of about 21,799 (237)

Trading between perceived risks and benefits related to biosimilar biological treatment in Crohn’s disease; discrete choice experiment among gastroenterologists [PDF]

, 2015
Objective: The objective of the study is to explore preferences of gastroenterologists for biosimilar drugs in Crohn’s Disease and reveal trade-offs between the perceived risks and benefits related to biosimilar drugs.
Baji, Petra, Brodszky, Valentin, Golovics, Petra A., Gulácsi, László, Lakatos, Péter L., Lovász, Barbara D., Péntek, Márta, Rencz, Fanni   +7 more
core  

A Phase 3 Multicenter, Double‐Blind Study Comparing Efficacy, Safety, Immunogenicity, and Pharmacokinetics of Alkem's Biosimilar Teriparatide Versus Reference Teriparatide in Postmenopausal Osteoporosis

Aging Medicine
Objective The primary purpose of this study was to compare the efficacy and safety of proposed biosimilar teriparatide with reference teriparatide in patients of postmenopausal osteoporosis.
Nitin Kapoor, Thomas Paul, Rajeshwar Nath Srivastava, Saurabh Singh, Sunil Maheshwari, Vishal Patil, Awadhesh Kumar Yadav, Girish Bhatia, Sushil H. Mankar, Joe Joseph Cherian, Surabhi Maheshwari, Sudeepti Srivastava, Dattatray Pawar, Roshan Pawar, Amol Aiwale, Amitrajit Pal, Yogesh Rane, Vinayaka Shahavi, Akhilesh Sharma   +18 more
doaj   +1 more source

India's Health Diplomacy: Advancing Pharmaceutical and MedTech Leadership in the Global South

World Medical &Health Policy, Volume 18, Issue 1, March 2026.
ABSTRACT Health diplomacy has become a pivotal aspect of India's engagement with the Global South, intertwining foreign policy, public health, and global collaboration to address disparities while pursuing strategic interests. India's pharmaceutical industry, which accounts for nearly 20% of the world's generics, has positioned the nation as the ...
Gaurav Chanderprakash Mittal, Vijay Kumar Chattu, Prakash Narayanan, Rahul Clare, Cherian Varghese   +4 more
wiley   +1 more source

Making Advanced Therapies Affordable and Accessible: Two Strategic Approaches

Developing World Bioethics, Volume 26, Issue 1, Page 66-78, March 2026.
ABSTRACT This article explores two complementary strategies for addressing the affordability and access challenges facing advanced therapies. As high development costs and limited market access have led to the withdrawal of several therapies, the article examines how these barriers create ‘valleys of death’ that prevent innovation from reaching ...
Ubaka Ogbogu, Lauren Albrecht
wiley   +1 more source

Biosimilar medicines and cost-effectiveness

ClinicoEconomics and Outcomes Research, 2011
Steven SimoensResearch Centre for Pharmaceutical Care and Pharmaco-economics, Faculty of Pharmaceutical Sciences, Katholieke Universiteit Leuven, Leuven, BelgiumAbstract: Given that biosimilars are agents that are similar but not identical to the ...
Steven Simoens
doaj  

Comparing of Efficacy and Safety Between Sintilimab Plus IBI305 and PD‐1 Inhibitor Plus TKIs in Combination of TACE for uHCC

Liver International, Volume 46, Issue 3, March 2026.
ABSTRACT Background Systemic therapy combined with transcatheter arterial chemoembolization (TACE) is the main treatment strategy for patients with unresectable hepatocellular carcinoma (uHCC). Nevertheless, there are currently few direct comparative studies between different combined treatment regimens.
Houxiang Ya, Kai Wang, Huixia Qin, Yi Zhou, Hesheng Lin, Chengyuan Liu, Kaiwen Jiang, Jing Gu, Shuqun Li   +8 more
wiley   +1 more source

Long-term safety and efficacy of biosimilar infliximab among patients with inflammatory arthritis switched from reference product

Open Access Rheumatology: Research and Reviews, 2017
Abuelmagd Abdalla, Niamh Byrne, Richard Conway, Thomas Walsh, Geraldine Mannion, Michael Hanly, Miriam O’Sullivan, Ann Maria Curran, John J Carey Department of Rheumatology, Galway University Hospitals, Galway ...
Abdalla A, Byrne N, Conway R, Walsh T, Mannion G, Hanly M, O'Sullivan M, Curran AM, Carey JJ   +8 more
doaj  

Early Initiation of Anti‐TNF Biosimilar in Newly Diagnosed Moderate and Severe Crohn's Disease: Health Economic Insights From the PROFILE Trial

JCC Plus, Volume 1, Issue 2, March 2026.
Michal Prokopič
wiley   +1 more source

Comparable remission and health care use in real-world inflammatory bowel disease patients initiating originator biologics <i>vs</i> biosimilars. [PDF]

World J Gastroenterol
Moura CS, Etingin A, Lukusa L, Singh H, Narula N, Targownik LE, Leung Y, Zezos P, Polewiczowska-Nowak B, Afif W, Bernatsky S.   +10 more
europepmc   +1 more source

Sandoz Inc. v. Amgen Inc.: Removing Barriers to Market Access for Biosimilar Manufacturers [PDF]

, 2019
Koya, Moyosore O.
core   +1 more source